NBTX Stock Analysis: Buy, Sell, or Hold?
NBTX - Nanobiotix S.A. American Depositary Shares
$38.40
-1.08 (-2.74%)
▼
5d:
+11.53%
30d:
+4.46%
90d:
+12.71%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Apr 28, 2026
0d
Get Alerted When NBTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NBTX shows positive signals but monitor for confirmation. Market pricing in 47.1% growth. Moderate conviction.
💡 BUY OPPORTUNITY: NBTX shows positive signals but monitor for confirmation. Market pricing in 47.1% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NBTX is currently trading at $38.40, which is considered slightly high relative to its 30-day fair value range of $34.74 to $38.79. From a valuation perspective, the stock is trading at a premium (Forward PE: 568.0) compared to its historical average (178.3). At these levels, the market is pricing in 47.1% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, NBTX is in a uptrend. Immediate support is located at $33.12, while resistance sits at $39.90.
Market Sentiment: NBTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $43.51 (+13.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NBTX is in a uptrend. Immediate support is located at $33.12, while resistance sits at $39.90.
Market Sentiment: NBTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $43.51 (+13.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$34.74 -
$38.79
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.0%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($43.51)
- BEARISH: Market expects 47.1% growth - appears too optimistic based on history
Trading Range Analysis
30-Day Trading Range
$34.74 -
$38.79
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$33.12
Resistance Level
$39.90
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
568.05
Wall Street Target
$43.51
(+13.3%)
Revenue Growth (YoY)
186.8%
Profit Margin
-73.5%
Valuation Premium vs History
+47.1% premium
PE vs Historical
568.1 vs 178.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+47.1%
(market-implied from PE analysis)
1-Year Target
$56.49
(+47%)
2-Year Target
$83.09
(+116%)
3-Year Target
$122.23
(+218%)
3-Yr Target (if PE normalizes)
(PE: 568→178)
PE COMPRESSION
$38.37
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 568.0, Growth: 59.1%)
$129.60
(+238%)
Base:
(SPY PE: 21.8, Growth: 59.1%)
$4.97
(-87%)
Bear:
(PE: 18.5, Growth: 59.1%)
$4.22
(-89%)
Share & Embed Analysis
Last updated: July 02, 2026 10:55 PM ET
Data refreshes hourly during market hours. Next update: 11:55 PM
Data refreshes hourly during market hours. Next update: 11:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
